Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Nascimento

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Neuromuscular Disorders : NMD|September 7, 2020
Gain and loss of abilities in type II SMA: A 12-month natural history studyGiorgia Coratti, Simona Lucibello, Maria C Pera, et al.
Annals of Clinical and Translational Neurology|May 2, 2024
Epilepsy in Duchenne and Becker muscular dystrophiesJesus Alfonso Armijo Gómez, Miguel A Fernandez-Garcia, Ana Camacho, et al.
Acta Neuropathologica Communications|February 13, 2025
Blood biomarker fingerprints in a cohort of patients with CHRNE-related congenital myasthenic syndromeAdela Della Marina, Andrie Koutsoulidou, Daniel Natera-de Benito, et al.
Journal of Neuromuscular Diseases|May 20, 2026
Nucleoside therapy for thymidine kinase 2 deficiency: Long-term outcomes from a Brazilian cohortCristiane Araujo Martins Moreno, Tatiana Ribeiro Fernandes, Clara Gontijo Camelo, et al.
Neurology. Genetics|March 28, 2024
Clinical and Genetic Analysis of Patients With TK2 DeficiencyFrancisco Ceballos, Pablo Serrano-Lorenzo, Laura Bermejo-Guerrero, et al.
Journal of Neurology|February 3, 2023
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)Maryam Oskoui, John W Day, Nicolas Deconinck, et al.
Pediatric Neurology|June 4, 2024
Advancing the Understanding of Vesicle-Associated Membrane Protein 1-Related Congenital Myasthenic Syndrome: Phenotypic Insights, Favorable Response to 3,4-Diaminopyridine, and Clinical Characterization of Five New CasesDaniel Natera-de Benito, Alessia Pugliese, Kiran Polavarapu, et al.
Journal of Neurology|January 2, 2021
COVID-19 in children with neuromuscular disordersDaniel Natera-de Benito, Sergio Aguilera-Albesa, Laura Costa-Comellas, et al.
Neuromuscular Disorders : NMD|January 12, 2023
A novel phenotype of AChR-deficiency syndrome with predominant facial and distal weakness resulting from the inclusion of an evolutionary alternatively-spliced exon in CHRNA1Pedro M Rodríguez Cruz, Gianina Ravenscroft, Daniel Natera, et al.
The Lancet. Neurology|December 23, 2021
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trialEugenio Mercuri, Nicolas Deconinck, Elena S Mazzone, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Neuromuscular Disorders : NMD|September 7, 2020
Gain and loss of abilities in type II SMA: A 12-month natural history studyGiorgia Coratti, Simona Lucibello, Maria C Pera, et al.
Annals of Clinical and Translational Neurology|May 2, 2024
Epilepsy in Duchenne and Becker muscular dystrophiesJesus Alfonso Armijo Gómez, Miguel A Fernandez-Garcia, Ana Camacho, et al.
Acta Neuropathologica Communications|February 13, 2025
Blood biomarker fingerprints in a cohort of patients with CHRNE-related congenital myasthenic syndromeAdela Della Marina, Andrie Koutsoulidou, Daniel Natera-de Benito, et al.
Journal of Neuromuscular Diseases|May 20, 2026
Nucleoside therapy for thymidine kinase 2 deficiency: Long-term outcomes from a Brazilian cohortCristiane Araujo Martins Moreno, Tatiana Ribeiro Fernandes, Clara Gontijo Camelo, et al.
Neurology. Genetics|March 28, 2024
Clinical and Genetic Analysis of Patients With TK2 DeficiencyFrancisco Ceballos, Pablo Serrano-Lorenzo, Laura Bermejo-Guerrero, et al.
Journal of Neurology|February 3, 2023
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)Maryam Oskoui, John W Day, Nicolas Deconinck, et al.
Pediatric Neurology|June 4, 2024
Advancing the Understanding of Vesicle-Associated Membrane Protein 1-Related Congenital Myasthenic Syndrome: Phenotypic Insights, Favorable Response to 3,4-Diaminopyridine, and Clinical Characterization of Five New CasesDaniel Natera-de Benito, Alessia Pugliese, Kiran Polavarapu, et al.
Journal of Neurology|January 2, 2021
COVID-19 in children with neuromuscular disordersDaniel Natera-de Benito, Sergio Aguilera-Albesa, Laura Costa-Comellas, et al.
Neuromuscular Disorders : NMD|January 12, 2023
A novel phenotype of AChR-deficiency syndrome with predominant facial and distal weakness resulting from the inclusion of an evolutionary alternatively-spliced exon in CHRNA1Pedro M Rodríguez Cruz, Gianina Ravenscroft, Daniel Natera, et al.
The Lancet. Neurology|December 23, 2021
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trialEugenio Mercuri, Nicolas Deconinck, Elena S Mazzone, et al.
Pageof 6